Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buggisch

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Zeitschrift Fur Gastroenterologie|July 16, 2024
ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single centerSarah Lange, Christina Baehr, Nur Irem Cakman-Hinrichs, et al.
Zeitschrift Fur Gastroenterologie|February 11, 2020
Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R)Annika Schmitt, Rainer Günther, Stefan Mauss, et al.
Zeitschrift Fur Gastroenterologie|May 15, 2025
Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-RegistryEva Katharina Messer, David Petroff, Jörn Schattenberg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2017
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver diseaseChristophe Hézode, Piero L Almasio, Stefan Bourgeois, et al.
Gastroenterology|July 26, 2011
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeksChristoph Sarrazin, Susanne Schwendy, Bernd Möller, et al.
European Journal of Gastroenterology & Hepatology|July 14, 2020
Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry studyMaria M Gabriel, Gerald Kircheis, Svenja Hardtke, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2020
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD careWolf Peter Hofmann, Peter Buggisch, Lisa Schubert, et al.
Zeitschrift Fur Gastroenterologie|January 9, 2023
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-RegistryAndreas Geier, Monika Rau, Anita Pathil-Warth, et al.
Zeitschrift Fur Gastroenterologie|January 15, 2019
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]Dietrich Hüppe, Yvonne Serfert, Peter Buggisch, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Zeitschrift Fur Gastroenterologie|July 16, 2024
ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single centerSarah Lange, Christina Baehr, Nur Irem Cakman-Hinrichs, et al.
Zeitschrift Fur Gastroenterologie|February 11, 2020
Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R)Annika Schmitt, Rainer Günther, Stefan Mauss, et al.
Zeitschrift Fur Gastroenterologie|May 15, 2025
Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-RegistryEva Katharina Messer, David Petroff, Jörn Schattenberg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2017
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver diseaseChristophe Hézode, Piero L Almasio, Stefan Bourgeois, et al.
Gastroenterology|July 26, 2011
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeksChristoph Sarrazin, Susanne Schwendy, Bernd Möller, et al.
European Journal of Gastroenterology & Hepatology|July 14, 2020
Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry studyMaria M Gabriel, Gerald Kircheis, Svenja Hardtke, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2020
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD careWolf Peter Hofmann, Peter Buggisch, Lisa Schubert, et al.
Zeitschrift Fur Gastroenterologie|January 9, 2023
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-RegistryAndreas Geier, Monika Rau, Anita Pathil-Warth, et al.
Zeitschrift Fur Gastroenterologie|January 15, 2019
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]Dietrich Hüppe, Yvonne Serfert, Peter Buggisch, et al.
Pageof 11